Core Viewpoint - Analysts project that Merck (MRK) will report quarterly earnings of $1.99 per share, reflecting a 12.7% decline year over year, with revenues expected to reach $15.71 billion, down 2.5% from the same quarter last year [1]. Earnings Projections - The consensus EPS estimate has been revised downward by 1.1% in the past 30 days, indicating a reassessment by covering analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Revenue Estimates - Analysts estimate 'Sales- Oncology- Keytruda' at $7.90 billion, indicating an 8.7% year-over-year increase [5]. - 'Sales- Vaccines- Gardasil' is projected at $1.30 billion, reflecting a significant decline of 47.5% from the prior-year quarter [5]. - 'Sales- Animal health' is expected to reach $1.55 billion, suggesting a 4.5% year-over-year increase [5]. Oncology Sales Breakdown - 'Sales- Oncology- Alliance revenue- Lenvima' is estimated at $244.01 million, down 2% from the year-ago quarter [6]. - 'Sales- Oncology- Keytruda - U.S.' is projected at $4.67 billion, reflecting a 5.9% increase year over year [6]. - 'Sales- Oncology- Keytruda - International' is expected to reach $3.16 billion, indicating a 10.4% year-over-year increase [6]. Additional Oncology Revenue Estimates - 'Sales- Oncology- Alliance revenue- Lynparza - U.S.' is expected to be $140.82 million, down 8% from the previous year [7]. - 'Sales- Oncology- Alliance revenue- Lynparza - International' is projected at $185.43 million, reflecting a 12.4% year-over-year increase [7]. - 'Sales- Oncology- Alliance revenue- Lenvima - U.S.' is estimated at $178.30 million, indicating a 0.7% increase from the year-ago quarter [8]. - 'Sales- Oncology- Alliance revenue- Lenvima - International' is expected to be $73.72 million, reflecting a 1% increase year over year [8]. Hospital Acute Care Sales - 'Sales- Hospital Acute Care- Zerbaxa - U.S.' is projected to reach $36.85 million, indicating an 11.7% increase from the prior-year quarter [9]. - 'Sales- Hospital Acute Care- Zerbaxa - International' is expected to be $29.97 million, reflecting a 7.1% year-over-year increase [9]. Stock Performance - Over the past month, Merck shares have recorded a return of +5.4%, compared to the Zacks S&P 500 composite's +5.7% change [9]. - Based on its Zacks Rank 4 (Sell), Merck is expected to underperform the overall market in the upcoming period [9].

For the quarter ended March 2025, Merck (MRK) reported revenue of $15.53 billion, down 1.6% over the same period last year. EPS came in at $2.22, compared to $2.07 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $15.39 billion, representing a surprise of +0.93%. The company delivered an EPS surprise of +3.26%, with the consensus EPS estimate being $2.15.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they co ...

Core Viewpoint - Analysts forecast Merck's quarterly earnings to be $2.16 per share, reflecting a year-over-year increase of 4.4%, while revenues are expected to decline by 1.9% to $15.48 billion [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 4%, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock performance [3]. Key Metrics Projections - Sales for Oncology product Keytruda are projected to reach $7.55 billion, an increase of 8.7% year-over-year [5]. - Hospital Acute Care sales for Zerbaxa are expected to be $63.07 million, reflecting a 12.6% increase from the previous year [5]. - Alliance revenue for Lynparza is estimated at $300.62 million, indicating a 3% increase year-over-year [5]. - Sales for Oncology Alliance revenue Lenvima are projected at $234.33 million, showing an 8.1% decline from the prior year [6]. - U.S. sales for Keytruda are expected to be $4.47 billion, reflecting an 8.6% increase year-over-year [6]. - International sales for Keytruda are projected at $3.08 billion, indicating an 8.8% increase from the previous year [7]. - U.S. sales for Lynparza are expected to reach $121.96 million, reflecting a 9.7% decline year-over-year [7]. - International sales for Lynparza are projected at $178.66 million, indicating a 13.8% increase from the prior year [8]. - U.S. sales for Lenvima are expected to be $155.59 million, reflecting a 10.1% decline year-over-year [8]. - International sales for Lenvima are projected at $78.74 million, indicating a 4% decline from the previous year [9]. - U.S. sales for Zerbaxa are expected to reach $36.81 million, reflecting an 11.5% increase year-over-year [9]. - International sales for Zerbaxa are projected at $26.26 million, indicating a 14.2% increase from the prior year [10]. Stock Performance - Merck's shares have decreased by 17.7% over the past month, compared to a 6.9% decline in the Zacks S&P 500 composite [10].